A Myriad of Pathways to NASH

被引:33
|
作者
Larrain, Soledad [1 ]
Rinella, Mary E. [1 ]
机构
[1] Northwestern Univ, Div Gastroenterol & Hepatol, Dept Med, Feinberg Sch Med, Chicago, IL 60611 USA
关键词
Nonalcoholic fatty liver disease; Nonalcoholic steatohepatitis; NASH; Drug; Nutrition; Endocrine; Metabolism; NONALCOHOLIC FATTY LIVER; INTESTINAL BACTERIAL OVERGROWTH; MITOCHONDRIAL BETA-OXIDATION; INFLAMMATORY-BOWEL-DISEASE; HEPATIC CB1 RECEPTORS; CHAIN ACYL-COENZYME; PLASMA-FREE CHOLINE; GROWTH-HORMONE; PARENTERAL-NUTRITION; INSULIN-RESISTANCE;
D O I
10.1016/j.cld.2012.05.009
中图分类号
R57 [消化系及腹部疾病];
学科分类号
摘要
Nonalcoholic steatohepatitis (NASH) is defined histopathologically by the presence of macrovesicular steatosis, cellular ballooning, and inflammation. NASH represents a complex multifactorial disease that typically occurs within the context of the metabolic syndrome. NASH lacks homogeneity, and other forms of NASH can present atypically. Less than 50% of patients with NASH respond to pharmacologic treatment, which speaks to this heterogeneity. The authors discuss drugs, disease entities, and nutritional states that can cause or exacerbate underlying NASH indirectly through worsening insulin resistance or directly by interfering with lipid metabolism, promoting oxidative injury, or activating inflammatory pathways.
引用
收藏
页码:525 / +
页数:26
相关论文
共 50 条
  • [1] NASH and HCC
    Page, John M.
    Harrison, Stephen A.
    CLINICS IN LIVER DISEASE, 2009, 13 (04) : 631 - +
  • [2] Insulin resistance in NASH
    Choudhury, J
    Sanyal, AJ
    FRONTIERS IN BIOSCIENCE-LANDMARK, 2005, 10 : 1520 - 1533
  • [3] Icosabutate: targeting metabolic and inflammatory pathways for the treatment of NASH
    Fraser, David A.
    Harrison, Stephen A.
    Schuppan, Detlef
    EXPERT OPINION ON INVESTIGATIONAL DRUGS, 2022, 31 (12) : 1269 - 1278
  • [4] Immune and inflammatory pathways in NASH
    Ganz, Michal
    Szabo, Gyongyi
    HEPATOLOGY INTERNATIONAL, 2013, 7 : S771 - S781
  • [5] Immune and inflammatory pathways in NASH
    Michal Ganz
    Gyongyi Szabo
    Hepatology International, 2013, 7 : 771 - 781
  • [6] Folate and B12 Levels Correlate with Histological Severity in NASH Patients
    Mahamid, Mahmud
    Mahroum, Naim
    Bragazzi, Nicola Luigi
    Shalaata, Kasem
    Yavne, Yarden
    Adawi, Mohammad
    Amital, Howard
    Watad, Abdulla
    NUTRIENTS, 2018, 10 (04):
  • [7] Epigenetics in NAFLD/NASH: Targets and therapy
    Sodum, Nalini
    Kumar, Gautam
    Bojja, Sree Lalitha
    Kumar, Nitesh
    Rao, C. Mallikarjuna
    PHARMACOLOGICAL RESEARCH, 2021, 167
  • [8] Diet and exercise in NAFLD/NASH: Beyond the obvious
    Semmler, Georg
    Datz, Christian
    Reiberger, Thomas
    Trauner, Michael
    LIVER INTERNATIONAL, 2021, 41 (10) : 2249 - 2268
  • [9] ASH and NASH
    Scaglioni, F.
    Ciccia, S.
    Marino, M.
    Bedogni, G.
    Bellentani, S.
    DIGESTIVE DISEASES, 2011, 29 (02) : 202 - 210
  • [10] NASH in HIV
    Cervo, Adriana
    Shengir, Mohamed
    Patel, Keyur
    Sebastiani, Giada
    CURRENT HIV/AIDS REPORTS, 2020, 17 (06) : 601 - 614